Search research articles
Contact Us
Filters
Showing results (241-250 of 512) with videos related to
Page
of 52
Sort By:
Frontiers in Immunology
|
November 10, 2022
Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report
Mihaela Aldea, Rakiba Belkhir, Emeline Colomba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 21, 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Jordi Remon, Martina Bortolot, Paolo Bironzo, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
February 26, 2014
Is sacrifying the phrenic nerve during thymoma resection worthwhile?
Sarah Hamdi, Olaf Mercier, Elie Fadel, et al.
JAMA Network Open
|
September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer
Adrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Molecular Cancer Therapeutics
|
October 9, 2021
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Brion W Murray, Evan Rogers, Dayong Zhai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2024
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers
Pierre-Louis Cariou, Cédric Pobel, Jean-Marie Michot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2024
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, et al.
Nature Reviews. Clinical Oncology
|
July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges
Giannis Mountzios, Jordi Remon, Lizza E L Hendriks, et al.
Cardiovascular and Interventional Radiology
|
November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer
Pernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Romain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
Page
of 52
Search research articles
Search
Showing results (241-250 of 512) with videos related to
Sort By:
Page
of 52
Frontiers in Immunology
|
November 10, 2022
Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report
Mihaela Aldea, Rakiba Belkhir, Emeline Colomba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 21, 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Jordi Remon, Martina Bortolot, Paolo Bironzo, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
February 26, 2014
Is sacrifying the phrenic nerve during thymoma resection worthwhile?
Sarah Hamdi, Olaf Mercier, Elie Fadel, et al.
JAMA Network Open
|
September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer
Adrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Molecular Cancer Therapeutics
|
October 9, 2021
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Brion W Murray, Evan Rogers, Dayong Zhai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2024
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers
Pierre-Louis Cariou, Cédric Pobel, Jean-Marie Michot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2024
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, et al.
Nature Reviews. Clinical Oncology
|
July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges
Giannis Mountzios, Jordi Remon, Lizza E L Hendriks, et al.
Cardiovascular and Interventional Radiology
|
November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer
Pernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Romain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
Page
of 52